Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats

Hypolipidemic drugs are inhibitors of phosphatidylcholine synthesis.

“…Yet, cholesterol circulation appears to be affected more severely by the drugs' ability to decrease cholesterol transport from the liver and to cause cholesterol deposition in the liver (14,15,38).…”

“…The effectiveness of these agents generally has been attributed to their ability to interfere with certain phases of fatty acid (15,18,(20)(21)(22)(23), triglyceride (8,(23)(24)(25)(26)(27)(28)(29)(30)(31), and cholesterol (11,14,15,(32)(33)(34)(35)(36)(37)(38)(39) metabolism, but the precise or prevalent mode of action of any of these drugs is not understood.…”

“…Clofibrate (ethyl p-chlorophenoxyisobutyrate) has been studied and used extensively (3)(4)(5), but less is known about the biochemical and physiological effects of various other hypolipidemic agents such as tibric acid [2-chloro-5-(cis-3,5-dimethylpiperidinosulfonyl)benzoicacid] (4,6-8), SaH-42-348f1-methyl-4-piperidyl bis-(p-chlorophenoxy)acetate] (9, 10), S-321328 [(4R)-4-(2,3,4,6,6ap,7,8,9,9aa,9b,-decahydro-6a/3-methyl- '3 -oxo-lH-cyclopenta[f]-quinolin-7,B3yl)valeric acid (11), WY-14643 ([4-chloro-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) (4,(12)(13)(14), S-8527 (1,1-bis-[4'-(1"-carboxy-1"-methylpropoxy)phenyl]cyclohexane) (15)(16)(17)(18)(19), and DH-990 (2-[3,5-di-(t-butyl-4-hydroxyphenyl)thio]hexanoic acid) (4). The effectiveness of these agents generally has been attributed to their ability to interfere with certain phases of fatty acid (15,18,(20)(21)(22)(23), triglyceride (8,(23)(24)(25)(26)(27)(28)(29)(30)(31), and cholesterol (11,14,15,(32)(33)(34)(35)(36)(37)…”